EGFR and non-small cell lung carcinoma: In this retrospective study of EGFR‐mutant NSCLC patients with brain metastases who received EGFR‐TKIs for a first‐line drug therapy, upfront brain radiotherapy and TKI showed prolonged time to treatment failure compared to TKI alone.